View in EDS

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Saved in:
Bibliographic Details
Title: A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.
Authors: Brunner AM; Massachusetts General Hospital, Boston, Massachusetts, United States., Liu Y; Dana Farber Cancer Institute, Boston, Massachusetts, United States., Garcia JS; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Mendez LM; Yale University School of Medicine, New Haven, Connecticut, United States., Gutierrez C; Dana-Farber Cancer Institute; Harvard Medical School, Boston, Massachusetts, United States., Nonavinkere Srivatsan S; Washington University St Louis, Saint Louis, Missouri, United States., Shao J; Washington University School of Medicine, St. Louis, Missouri, United States., Aubrey BJ; Massachusetts General Hospital, United States., Amrein PC; Massachusetts General Hospital, Boston, Massachusetts, United States., Narayan R; Massachusetts General Hospital, Boston, Massachusetts, United States., Vedula RS; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Friedman E; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Neuberg DS; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Andrade Campos M; AstraZeneca, Barcelona, Spain., Smith SA; AstraZeneca, Cambridge, United Kingdom., Stone RM; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Fathi AT; Massachusetts General Hospital / Harvard Medical School, Boston, Massachusetts, United States., Walter MJ; Washington University School of Medicine, St. Louis, Missouri, United States., Graubert TA; Massachusetts General Hospital, Boston, Massachusetts, United States., Jacoby MA; Washington University School of Medicine, St. Louis, Missouri, United States.
Source: Blood advances [Blood Adv] 2026 Jun 30. Date of Electronic Publication: 2026 Jun 30.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42379235
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Brunner+AM%22">Brunner AM</searchLink>; Massachusetts General Hospital, Boston, Massachusetts, United States.<br /><searchLink fieldCode="AU" term="%22Liu+Y%22">Liu Y</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, United States.<br /><searchLink fieldCode="AU" term="%22Garcia+JS%22">Garcia JS</searchLink>; Dana-Farber Cancer Institute, Boston, Massachusetts, United States.<br /><searchLink fieldCode="AU" term="%22Mendez+LM%22">Mendez LM</searchLink>; Yale University School of Medicine, New Haven, Connecticut, United States.<br /><searchLink fieldCode="AU" term="%22Gutierrez+C%22">Gutierrez C</searchLink>; Dana-Farber Cancer Institute; Harvard Medical School, Boston, Massachusetts, United States.<br /><searchLink fieldCode="AU" term="%22Nonavinkere+Srivatsan+S%22">Nonavinkere Srivatsan S</searchLink>; Washington University St Louis, Saint Louis, Missouri, United States.<br /><searchLink fieldCode="AU" term="%22Shao+J%22">Shao J</searchLink>; Washington University School of Medicine, St. Louis, Missouri, United States.<br /><searchLink fieldCode="AU" term="%22Aubrey+BJ%22">Aubrey BJ</searchLink>; Massachusetts General Hospital, United States.<br /><searchLink fieldCode="AU" term="%22Amrein+PC%22">Amrein PC</searchLink>; Massachusetts General Hospital, Boston, Massachusetts, United States.<br /><searchLink fieldCode="AU" term="%22Narayan+R%22">Narayan R</searchLink>; Massachusetts General Hospital, Boston, Massachusetts, United States.<br /><searchLink fieldCode="AU" term="%22Vedula+RS%22">Vedula RS</searchLink>; Dana-Farber Cancer Institute, Boston, Massachusetts, United States.<br /><searchLink fieldCode="AU" term="%22Friedman+E%22">Friedman E</searchLink>; Dana-Farber Cancer Institute, Boston, Massachusetts, United States.<br /><searchLink fieldCode="AU" term="%22Neuberg+DS%22">Neuberg DS</searchLink>; Dana-Farber Cancer Institute, Boston, Massachusetts, United States.<br /><searchLink fieldCode="AU" term="%22Andrade+Campos+M%22">Andrade Campos M</searchLink>; AstraZeneca, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Smith+SA%22">Smith SA</searchLink>; AstraZeneca, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Stone+RM%22">Stone RM</searchLink>; Dana-Farber Cancer Institute, Boston, Massachusetts, United States.<br /><searchLink fieldCode="AU" term="%22Fathi+AT%22">Fathi AT</searchLink>; Massachusetts General Hospital / Harvard Medical School, Boston, Massachusetts, United States.<br /><searchLink fieldCode="AU" term="%22Walter+MJ%22">Walter MJ</searchLink>; Washington University School of Medicine, St. Louis, Missouri, United States.<br /><searchLink fieldCode="AU" term="%22Graubert+TA%22">Graubert TA</searchLink>; Massachusetts General Hospital, Boston, Massachusetts, United States.<br /><searchLink fieldCode="AU" term="%22Jacoby+MA%22">Jacoby MA</searchLink>; Washington University School of Medicine, St. Louis, Missouri, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2026 Jun 30. <i>Date of Electronic Publication: </i>2026 Jun 30.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42379235
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2026019848
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Brunner AM
      – PersonEntity:
          Name:
            NameFull: Liu Y
      – PersonEntity:
          Name:
            NameFull: Garcia JS
      – PersonEntity:
          Name:
            NameFull: Mendez LM
      – PersonEntity:
          Name:
            NameFull: Gutierrez C
      – PersonEntity:
          Name:
            NameFull: Nonavinkere Srivatsan S
      – PersonEntity:
          Name:
            NameFull: Shao J
      – PersonEntity:
          Name:
            NameFull: Aubrey BJ
      – PersonEntity:
          Name:
            NameFull: Amrein PC
      – PersonEntity:
          Name:
            NameFull: Narayan R
      – PersonEntity:
          Name:
            NameFull: Vedula RS
      – PersonEntity:
          Name:
            NameFull: Friedman E
      – PersonEntity:
          Name:
            NameFull: Neuberg DS
      – PersonEntity:
          Name:
            NameFull: Andrade Campos M
      – PersonEntity:
          Name:
            NameFull: Smith SA
      – PersonEntity:
          Name:
            NameFull: Stone RM
      – PersonEntity:
          Name:
            NameFull: Fathi AT
      – PersonEntity:
          Name:
            NameFull: Walter MJ
      – PersonEntity:
          Name:
            NameFull: Graubert TA
      – PersonEntity:
          Name:
            NameFull: Jacoby MA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 30
              M: 06
              Text: 2026 Jun 30
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1